NASDAQ:AUPH (Aurinia Pharmaceuticals Inc.)
About AUPH
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) Latest News
Coronavirus
3 TSX Stocks Bay Street Expects Could Double or Triple in 1 Year!
Investing
Value Investors: 1 Pharma Growth Stock With Huge Potential
Stocks for Beginners
3 Top Canadian Pharma Stocks for Ambitious Investors
Top TSX Stocks
3 BioPharm Stocks Yielding 100% Yearly Returns
Investing
3 Stocks That Could Benefit From Canada’s Population Boom
Investing
Which Canadian Healthcare Stocks Could Make You Rich?
Investing
This Unloved Drug Stock Could Have Massive Upside
Investing
3 High-Performing Stocks to Buy on the Dip
Investing
TSX Reaches 16,000: These Are 5 of the Highest-Performing Stocks This Year
Dividend Stocks
3 Stocks That Have Soared Higher Than Shopify Inc. This Year!
❮2